secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIOMARIN PHARMACEUTICAL INC (BMRN)
CIK:        0001048477
Form:       8-K
Filed at:   2026-01-26T23:59:59+00:00
Accession:  0001193125-26-021718
Event type: debt
Sentiment:  neutral
Materiality: 0.80
Item codes: 2.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioMarin guides ~$3.2B FY2025 revenue; plans $850M notes + $2.8B loans for Amicus deal
--------------------------------------------------------------------------------

- FY2025 preliminary total revenue ~$3.2B, including ~$920M from VOXZOGO; cash & investments ~$2.1B.
- Launches $850M senior notes due 2034 and $2.8B in term loans ($2B Term Loan B + $800M Term Loan A) plus $600M revolver.
- Proceeds escrowed; notes due Dec 2034 subject to special mandatory redemption at 100% if Amicus acquisition fails to close by Dec 19, 2026.
- Acquisition of Amicus expected to close in Q2 2026, subject to Amicus stockholder vote and antitrust clearance.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1048477/000119312526021718/0001193125-26-021718-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1048477/000119312526021718/d100834d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-021718

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer